Risk of developing elevated aCL, LA, and anti-β2-GPI antibodies between patients with solid tumors and healthy controls (n = 11 studies)
| Cancer type (no. of studies) . | No. of positive patients /total (%) . | No. of positive controls /total (%) . | RR (95% CI) . |
|---|---|---|---|
| Anticardiolipin antibodies | |||
| GI (n = 5)26-30 | 44/235 (18.7) | 11/302 (3.6) | 5.1 (2.6-9.95) |
| GU (n = 2)30,31 | 16/49 (32.7) | 7/140 (5.0) | 7.3 (3.3-16.2) |
| Breast (n = 2)30,32 | 3/62 (4.8) | 4/137 (2.9) | 1.9 (0.19-19.85) |
| CNS (n = 1)30 | 0/2 | 3/88 (3.4) | 4.3 (0.28-65.0) |
| Lung (n = 1)30 | 5/28 (17.9) | 3/88 (3.4) | 5.2 (1.3-20.6) |
| Melanoma (n = 1)30 | 0/3 | 3/88 (3.4) | 3.2 (0.20-51.7) |
| Various types of solid tumors (n = 2)25,30 * | 8/165 (4.9) | 4/346 (1.2) | 6.5 (2.1-20.3) |
| Anti-β2-GPI antibodies | |||
| GI (n = 2)26,33 | 9/119 (7.6) | 6/153 (3.9) | 1.7 (0.64-4.4) |
| Various types of solid tumors (n = 1)25 * | 0/142 | 1/258 (< 1) | 0.60 (0.02-14.7) |
| LA | |||
| Various types of solid tumors (n = 1) 25 * | 1/142 (< 1) | 0/258 | 5.4 (0.22-132.5) |
| Unspecified aPL antibodies | |||
| Breast (n = 1)34 | 19/77 (24.7) | 6/137 (4.4) | 5.6 (2.4-13.5) |
| GI (n = 1)34 | 7/21 (33.3) | 6/137 (4.4) | 7.6 (2.8-20.5) |
| GU (n = 1)35-39 | 32/134 (23.9) | 0/20 | 10.1 (0.64-158.95) |
| Head and neck (n = 1)34 | 4/16 (25.0) | 6/137 (4.4) | 5.7 (1.8-18.1) |
| Lung (n = 1)34 | 2/8 (25.0) | 6/137 (4.4) | 5.7 (1.4-23.9) |
| Various types of solid tumor (n = 1) 25 * | 2/142 (1.4) | 2/258 (<1) | 1.8 (0.26-12.8) |
| Cancer type (no. of studies) . | No. of positive patients /total (%) . | No. of positive controls /total (%) . | RR (95% CI) . |
|---|---|---|---|
| Anticardiolipin antibodies | |||
| GI (n = 5)26-30 | 44/235 (18.7) | 11/302 (3.6) | 5.1 (2.6-9.95) |
| GU (n = 2)30,31 | 16/49 (32.7) | 7/140 (5.0) | 7.3 (3.3-16.2) |
| Breast (n = 2)30,32 | 3/62 (4.8) | 4/137 (2.9) | 1.9 (0.19-19.85) |
| CNS (n = 1)30 | 0/2 | 3/88 (3.4) | 4.3 (0.28-65.0) |
| Lung (n = 1)30 | 5/28 (17.9) | 3/88 (3.4) | 5.2 (1.3-20.6) |
| Melanoma (n = 1)30 | 0/3 | 3/88 (3.4) | 3.2 (0.20-51.7) |
| Various types of solid tumors (n = 2)25,30 * | 8/165 (4.9) | 4/346 (1.2) | 6.5 (2.1-20.3) |
| Anti-β2-GPI antibodies | |||
| GI (n = 2)26,33 | 9/119 (7.6) | 6/153 (3.9) | 1.7 (0.64-4.4) |
| Various types of solid tumors (n = 1)25 * | 0/142 | 1/258 (< 1) | 0.60 (0.02-14.7) |
| LA | |||
| Various types of solid tumors (n = 1) 25 * | 1/142 (< 1) | 0/258 | 5.4 (0.22-132.5) |
| Unspecified aPL antibodies | |||
| Breast (n = 1)34 | 19/77 (24.7) | 6/137 (4.4) | 5.6 (2.4-13.5) |
| GI (n = 1)34 | 7/21 (33.3) | 6/137 (4.4) | 7.6 (2.8-20.5) |
| GU (n = 1)35-39 | 32/134 (23.9) | 0/20 | 10.1 (0.64-158.95) |
| Head and neck (n = 1)34 | 4/16 (25.0) | 6/137 (4.4) | 5.7 (1.8-18.1) |
| Lung (n = 1)34 | 2/8 (25.0) | 6/137 (4.4) | 5.7 (1.4-23.9) |
| Various types of solid tumor (n = 1) 25 * | 2/142 (1.4) | 2/258 (<1) | 1.8 (0.26-12.8) |
Cancer types included GI, GU, breast, lung, melanoma, head and neck, and other solid tumors.